Nosocomial infections are an important cause of morbi-mortality worldwide. The increase in the rate of resistance to conventional drugs in these microorganisms has stimulated the search for new therapeutic options. The nitro moiety (NO2) is an important pharmacophore of molecules with high anti-infective activity. We aimed to synthesize new nitro-derivates and to evaluate their antibacterial and anti-Candida potential in vitro. Five compounds [3-nitro-2-phenylchroman-4-ol (3); 3-nitro-2-phenyl-2H-chromene (4a); 3-nitro-2-(4-chlorophenyl)-2H-chromene (4b); 3-nitro-2-(4-fluorophenyl)-2H-chromene (4c), and 3-Nitro-2-(2,3-dichlorophenyl)-2H-chromene (4d)] were efficiently synthesized by Michael-aldol reaction of 2-hydroxybenzaldehyde with nitrostyrene, resulting in one β-nitro-alcohol (3) and four nitro-olefins (4a-4d). The antibacterial and anti-Candida potentials were evaluated by assaying minimal inhibitory concentration (MIC), minimum fungicidal concentration (MFC), and minimum bactericidal concentration (MBC). Mono-halogenated nitro-compounds (4b and 4c) showed anti-staphylococcal activity with MIC values of 15.6-62.5 μg/mL and MBC of 62.5 μg/mL. However, the activity against Gram-negative strains was showed to be considerably lower and our data suggests that this effect was associated with the outer membrane. Furthermore, nitro-compounds 4c and 4d presented activity against Candida spp. with MIC values ranging from 7.8-31.25 μg/mL and MFC of 15.6-500 μg/mL. In addition, these compounds were able to induce damage in fungal cells increasing the release of intracellular material, which was associated with actions on the cell wall independent of quantitative changes in chitin and β-glucan. Together, these findings show that nitro-compounds can be exploited as anti-staphylococcal and anti-Candida prototypes.

Departamento de Microbiologia Instituto de Ciências Biológicas Universidade Federal de Minas Gerais Belo Horizonte Minas Gerais Brazil

Laboratório de Microbiologia Médica Universidade Federal de São João del Rei Campus Centro Oeste Dona Lindu Universidade Federal de São João Del Rei Rua Sebastião Gonçalves Coelho 400 Chanadour Divinópolis Minas Gerais 35501 293 Brazil

Laboratório de Síntese Orgânica e Nanoestruturas Universidade Federal de São João del Rei Campus Centro Oeste Dona Lindu Divinópolis Minas Gerais Brazil

See more in PubMed

JAMA. 1995 Aug 23-30;274(8):639-44 PubMed

Bioorg Med Chem. 2017 Nov 1;25(21):6039-6048 PubMed

Bioorg Med Chem. 2014 May 15;22(10):2844-54 PubMed

Bioorg Med Chem. 2015 Nov 15;23(22):7292-301 PubMed

Clin Microbiol Rev. 1999 Oct;12(4):501-17 PubMed

J Nat Prod. 2008 Oct;71(10):1720-5 PubMed

Front Microbiol. 2016 Feb 02;6:1536 PubMed

Clin Infect Dis. 2009 Jan 1;48(1):1-12 PubMed

Eur J Med Chem. 2009 Jan;44(1):280-8 PubMed

Public Health Rep. 2007 Mar-Apr;122(2):160-6 PubMed

Sci Rep. 2015 Nov 10;5:16407 PubMed

Indian J Community Med. 2008 Apr;33(2):89-92 PubMed

Sci Rep. 2016 Jun 02;6:27258 PubMed

Curr Drug Targets. 2010 Mar;11(3):303-14 PubMed

Arch Microbiol. 2009 Sep;191(9):687-95 PubMed

Med Clin North Am. 2018 Sep;102(5):819-829 PubMed

Evid Based Complement Alternat Med. 2015;2015:925096 PubMed

Genetics. 2002 Oct;162(2):663-76 PubMed

Biochim Biophys Acta. 2013 Nov;1830(11):5193-203 PubMed

Eur J Clin Microbiol Infect Dis. 2018 Jun;37(6):1009-1019 PubMed

Nat Prod Res. 2018 Mar;32(6):723-731 PubMed

J Enzyme Inhib Med Chem. 2013 Dec;28(6):1291-9 PubMed

Biomed Pharmacother. 2019 Jan;109:1809-1818 PubMed

Eur J Med Chem. 2014 Oct 30;86:562-9 PubMed

Eur J Med Chem. 2014 Oct 30;86:364-7 PubMed

Chemosphere. 2018 Jul;203:368-380 PubMed

Antimicrob Agents Chemother. 2015 Sep;59(9):5631-40 PubMed

Lett Appl Microbiol. 2004;38(6):454-8 PubMed

Int J Antimicrob Agents. 2009 Jul;34(1):15-20 PubMed

J Antibiot (Tokyo). 2018 Aug;71(8):702-712 PubMed

Bioorg Med Chem Lett. 2014 Mar 1;24(5):1299-302 PubMed

Int Immunopharmacol. 2017 Feb;43:129-139 PubMed

Nature. 2015 Jan 22;517(7535):455-9 PubMed

Photodiagnosis Photodyn Ther. 2016 Mar;13:291-296 PubMed